peptide legality · 44 compounds × 51 jurisdictions

Peptide legality lookup: federal + state + sport-body status.

For each of 44 research peptides, this tool surfaces the FDA approval status, DEA schedule, 503A compounding posture, recent FDA Warning Letters, WADA/USADA/NCAA sport-body status, and any material state-level divergence — drawn from primary sources only, with verification dates on every citation.

§ 01

Look up a compound × state

compoundstate / jurisdiction

§ 02

How it works

What we cover

Each compound × state page surfaces three legal layers: (1) the federal posture — FDA approval / investigational / unapproved status, DEA scheduling, §503A compounding bulks-list status, PCAC review history, recent FDA Warning Letters, and the “research-use-only” sale-framing enforcement posture; (2) the state-specific layer — currently the ~12 states with material divergence from federal (controlled-substance scheduling, AG consumer-protection actions, telehealth restrictions, pharmacy-board enforcement); and (3) the sport-body layer — WADA 2026, USADA, NCAA banned-substance status with class codes.

Methodology

Every status field is sourced to a primary document — FDA Warning Letter, DEA orange book, WADA prohibited list PDF, state AG press release, or pharmacy-board order — with the verification date recorded inline. We do not cite secondary reporting except as background. When we couldn’t verify a specific claim against a primary source, the page lists it explicitly in the “what we couldn’t verify” section rather than asserting it. Every record has a lastVerified date.

Disclaimer

This is a research reference. It is not legal advice, not medical guidance, and not a substitute for either. Statuses change — FDA, DEA, WADA, and state AGs update their positions independently and frequently. The verified-date stamps are the floor on how current the entry is. Before making any decision that depends on this data, consult a licensed pharmacist (for compounding / medical-product questions) or a licensed attorney (for legal questions in your jurisdiction).

§ 03

What we couldn't verify

open questions and verification gaps

OEHHA Prop 65 status not directly verified against the master list for every compound.
Personal-possession enforcement posture is FDA-statement-based, not a positive legal exemption.
WADA capture under S0 (non-approved substances) and S2 (peptide hormones) is class-effect based, not always explicitly named.
State pharmacy-board enforcement actions are surfaced where AG press releases exist; private board orders may not be public.
Telehealth-specific peptide restrictions are an emerging area — state medical-board guidance often lags statutes.
Athletic-commission bans below the national-league level (state boxing/MMA commissions) are not exhaustively crawled.
Import status via personal-import-package guidance is FDA-discretionary and changes without rulemaking.
Compounding pharmacy 503A vs 503B distinctions are not surfaced per-state; only federal bulks-list status is tracked.
Veterinary-channel diversion (compounds also marketed for animal research) is not separately scoped.
Recent Warning Letter cadence is captured to the verifiedDate; new enforcement actions may have landed since.

§ 04

Read deeper

Other research tools — calculators, COA verifier
Peptide pricing index — what each compound actually costs per mg across audited vendors
Janoshik COA verifier — separate question from legality: did the test the vendor cites actually pass?

the roundup · monthly

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 subscribers· 0 sponsored items· 11 issues since launch